Aytu BioScience Inc (AYTU)
NASDAQ:AYTU
Want to see AYTU full AI Analyst Report?
AYTU Stock Chart & Stats
$2.60
-$0.06(-3.58%)
At close: 4:00 PM EST
$2.60
-$0.06(-3.58%)
Day’s Range― - ―
52-Week Range$0.98 - $3.07
Previous CloseN/A
Volume5.78K
Average Volume (3M)314.73K
Market Cap
$27.80M
Enterprise Value$14.11M
Total Cash (Recent Filing)$30.02M
Total Debt (Recent Filing)$23.07M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
May 18, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding10,733,208
10 Day Avg. Volume289,104
30 Day Avg. Volume314,725
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.72
Price to Sales (P/S)0.21
P/FCF Ratio-2.65
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue0.23
Enterprise Value/Gross Profit0.34
Enterprise Value/Ebitda-0.82
Forecast
1Y Price Target
$9.67Price Target Upside271.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.24
Revenue Forecast (FY)$57.06M
Bulls Say, Bears Say
Bulls Say
Clinical ProfileClinical data showing effective relief of depressive symptoms without labeled warnings for sexual dysfunction or weight gain versus placebo supports EXXUA's appeal to patients concerned about side effects.
Franchise RetentionSteady ADHD product sales and the RxConnect prescription management program indicate patient stickiness and reduced retail churn, which can sustain recurring revenue as the new product commercializes.
Regulatory ApprovalFDA approval of EXXUA as a first‑in‑class treatment for major depressive disorder establishes a differentiated market position that can attract prescribers seeking new mechanisms of action.
Bears Say
Commercial Execution RiskLaunching and commercializing a new psychiatric drug entails substantial sales and adoption challenges that raise the risk of commercial underperformance despite regulatory approval.
Pediatric Franchise WeaknessChoppy and declining pediatric franchise sales create uncertainty about the business's near‑term revenue contribution and may pressure overall growth unless performance stabilizes.
Aytu BioScience News
AYTU FAQ
What was Aytu BioScience Inc’s price range in the past 12 months?
Aytu BioScience Inc lowest stock price was $0.98 and its highest was $3.06 in the past 12 months.
What is Aytu BioScience Inc’s market cap?
Aytu BioScience Inc’s market cap is $27.80M.
When is Aytu BioScience Inc’s upcoming earnings report date?
Aytu BioScience Inc’s upcoming earnings report date is May 18, 2026 which is in 29 days.
How were Aytu BioScience Inc’s earnings last quarter?
Aytu BioScience Inc released its earnings results on Feb 03, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.407 by -$0.643.
Is Aytu BioScience Inc overvalued?
According to Wall Street analysts Aytu BioScience Inc’s price is currently Undervalued.
Does Aytu BioScience Inc pay dividends?
Aytu BioScience Inc does not currently pay dividends.
What is Aytu BioScience Inc’s EPS estimate?
Aytu BioScience Inc’s EPS estimate is -0.44.
How many shares outstanding does Aytu BioScience Inc have?
Aytu BioScience Inc has 10,733,208 shares outstanding.
What happened to Aytu BioScience Inc’s price movement after its last earnings report?
Aytu BioScience Inc reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.407. Following the earnings report the stock price went down -10.305%.
Which hedge fund is a major shareholder of Aytu BioScience Inc?
Currently, no hedge funds are holding shares in AYTU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aytu BioScience Inc
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
AYTU Company Deck
AYTU Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: strong strategic and commercial progress with the ExuA launch (first-in-class therapy, >100 prescribers, RxConnect-enabled access, and supply readiness) and resilient ADHD performance are meaningful positives. However, near-term financials show declines in net revenue, gross margin pressure (partly from a $600k write-down), higher operating spend for launch, a negative adjusted EBITDA, and a substantial reported net loss driven largely by an $8.2M non-cash derivative warrant loss. Early ExuA metrics are encouraging but limited by short launch duration and weather-related field disruption; cash levels are adequate but have declined modestly. Overall, positives around product launch and access are counterbalanced by near-term financial headwinds and potential generic risk.View all AYTU earnings summariesAYTU Stock 12 Month Forecast
Average Price Target
$9.67
▲(271.92% Upside)
Technical Analysis
Ownership Overview
3.99% Insiders
2.91% Mutual Funds
28.15% Other Institutional Investors
62.65% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---